Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

The startup agreed to pay Fosun Pharma as much as $645 million for a drug in testing for multiple lung conditions, including ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...

Miguel Fernández Alcalde, head of Merck KGaA’s U.S. arm, aims to “double down” on innovation. The company’s recent SpringWorks deal is just a start.

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...